Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns

Park I, Bayrouti A, MacIntyre D, Le V, Nguyen KB. Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns. Dermatol[...]

Closing the Gap: The Ethics of Non-Physician Delegation in Mohs Reconstruction

Li R, Ramirez Y, Stone L, Klufas T, Zhou AE, Tucci C, Beynet DP, Lo Sicco K, Grant-Kels JM. Closing the Gap: The Ethics of[...]

2026 Ebola Virus Disease Outbreak: What Dermatologists Should Know

Rosenbach M, Boghosian T, Granovsky R, Rimmer S, Chiu Y, Elewski BE, Rosmarin D, Said J, Trinidad JC, Zheng L, Goh C; American Academy of[...]